Firstly, noone, including Imugene, would offer 10x the current price.
And second, I don't think Imugene would be at all interested in acquiring Chimeric.They have everything they need already, and if they were looking for more assets it would likely be CD19 directed therapies to complement their OnCARlytics platform.
I think that is why Arovella has been pumped so hard, speculation of a buyout/licensing from Imugene.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)